Royal Bank Of Canada Coherus Bio Sciences, Inc. Transaction History
Royal Bank Of Canada
- $422 Billion
- Q1 2024
A detailed history of Royal Bank Of Canada transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 4,640 shares of CHRS stock, worth $8,027. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,640
Previous 31,932
85.47%
Holding current value
$8,027
Previous $106,000
89.62%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding CHRS
# of Institutions
148Shares Held
82.9MCall Options Held
184KPut Options Held
255K-
Black Rock Inc. New York, NY11.2MShares$19.4 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$18 Million0.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$17.4 Million0.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U07.38MShares$12.8 Million0.1% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$5.25 Million0.31% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $134M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...